| Ident. | Authors (with country if any) | Title |
|---|
| 000026 (2015) |
C. Warren [États-Unis] ; Raymond. Bartus [États-Unis] ; Tiffany. Baumann [États-Unis] ; Stewart Factor [États-Unis] ; Nicholas Boulis [États-Unis] ; Mark Stacy [États-Unis] ; Dennis. Turner [États-Unis] ; William Marks [États-Unis] ; Paul Larson [États-Unis] ; Phillip. Starr [États-Unis] ; Joseph Jankovic [États-Unis] ; Richard Simpson [États-Unis] ; Ray Watts [États-Unis] ; Barton Guthrie [États-Unis] ; Kathleen Poston [États-Unis] ; Jaimie. Henderson [États-Unis] ; Matthew Stern [États-Unis] ; Gordon Baltuch [États-Unis] ; Christopher. Goetz [États-Unis] ; Christopher Herzog [États-Unis] ; Jeffrey. Kordower [États-Unis] ; Ron Alterman [États-Unis] ; Andres. Lozano [Canada] ; Anthony. Lang [Canada] | Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. |
| 000055 (2014) |
Joseph Jankovic [États-Unis] ; Elijahu Berkovich [Israël] ; Eli Eyal [Israël] ; Eduardo Tolosa [Espagne] | Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: post-hoc analyses from the ADAGIO trial. |
| 000062 (2014) |
Rajesh Pahwa [États-Unis] ; Kelly. Lyons [États-Unis] ; Robert. Hauser [États-Unis] ; Stanley Fahn [États-Unis] ; Joseph Jankovic [États-Unis] ; Emmanuelle Pourcher [Canada] ; Ann Hsu [États-Unis] ; Martin O [États-Unis] ; Sherron Kell [États-Unis] ; Suneel Gupta [États-Unis] | Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. |
| 000070 (2014) |
Sotirios. Parashos [États-Unis] ; Sheng Luo ; Kevin. Biglan [États-Unis] ; Ivan Bodis ; Bo He ; Grace. Liang [États-Unis] ; G Ross [États-Unis] ; Barbara. Tilley ; Lisa. Shulman [États-Unis] | Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. |
| 000078 (2014) |
Nir Giladi [Israël] ; Liesbet Ghys [Belgique] ; Erwin Surmann [Allemagne] ; Babak Boroojerdi [États-Unis] ; Joseph Jankovic [États-Unis] | Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease. |
| 000090 (2014) |
Anthony. Nicholas [États-Unis] ; Rupam Borgohain [Inde] ; Pedro Chaná [Chili] ; Erwin Surmann [Allemagne] ; Emily. Thompson [Royaume-Uni] ; Lars Bauer [Allemagne] ; John Whitesides [États-Unis] ; Lawrence. Elmer [États-Unis] | A randomized study of rotigotine dose response on 'off' time in advanced Parkinson's disease. |
| 000159 (2012) |
Peter Lewitt [États-Unis] ; Babak Boroojerdi [États-Unis] ; Erwin Surmann [Allemagne] ; Werner Poewe [Autriche] | Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER |
| 000162 (2012) |
Andrew Lees [Royaume-Uni] ; Stanley Fahn ; Karla. Eggert ; Joseph Jankovic [États-Unis] ; Anthony Lang ; Federico Micheli ; M Mouradian ; Wolfgang. Oertel ; C Olanow ; Werner Poewe ; Olivier Rascol ; Eduardo Tolosa ; David Squillacote ; Dinesh Kumar | Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. |
| 000168 (2012) |
Lawrence. Elmer [États-Unis] ; Erwin Surmann ; Babak Boroojerdi ; Joseph Jankovic [États-Unis] | Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study. |
| 000175 (2012) |
| Design innovations and baseline findings in a long-term Parkinson’s trial: NET-PD LS-1 |
| 000234 (2011) |
Olivier Rascol [France] ; Cheryl. Fitzer ; Robert Hauser ; Joseph Jankovic [États-Unis] ; Anthony Lang ; J Langston ; Eldad Melamed ; Werner Poewe ; Fabrizio Stocchi ; Eduardo Tolosa ; Eli Eyal ; Yoni. Weiss ; C Olanow | A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. |
| 000515 (2010) |
William. Marks [États-Unis] ; Raymond. Bartus ; Joao Siffert ; Charles. Davis ; Andres Lozano ; Nicholas Boulis ; Jerrold Vitek ; Mark Stacy ; Dennis Turner ; Leonard Verhagen ; Roy Bakay ; Raymond Watts ; Barton Guthrie ; Joseph Jankovic [États-Unis] ; Richard Simpson ; Michele Tagliati ; Ron Alterman ; Matthew Stern ; Gordon Baltuch ; Philip. Starr ; Paul. Larson ; Jill. Ostrem ; John Nutt ; Karl Kieburtz ; Jeffrey. Kordower ; C Olanow | Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. |
| 000679 (2010) |
Fabrizio Stocchi [Italie] ; Olivier Rascol [France] ; Karl Kieburtz [États-Unis] ; Werner Poewe [Autriche] ; Joseph Jankovic [États-Unis] ; Eduardo Tolosa [Espagne] ; Paulo Barone [Italie] ; Anthony Lang [Canada] ; C Olanow [Italie, États-Unis] | Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study |
| 000687 (2010) |
Rodger Elble [États-Unis] ; Oksana Suchowersky [Canada] ; Stephanie Shaftman [Canada, États-Unis] ; William Weiner [États-Unis] ; Peng Huang [États-Unis] ; Barbara Tilley [États-Unis] | Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease |
| 000770 (2010) |
Steven Schwid [États-Unis] ; Janice Bausch [États-Unis] ; David Oakes [États-Unis] ; Lynn Schuchter [États-Unis] ; Caroline Tanner [États-Unis] ; Misser Forrest [Danemark] ; Anthony Lang [Canada] ; Ira Shoulson [États-Unis] | Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease |
| 000859 (2009) |
Joseph Jankovic [États-Unis] | Atomoxetine for freezing of gait in Parkinson disease. |
| 000864 (2009) |
C Olanow [États-Unis] ; Olivier Rascol ; Robert Hauser ; Paul. Feigin ; Joseph Jankovic [États-Unis] ; Anthony Lang ; William Langston ; Eldad Melamed ; Werner Poewe ; Fabrizio Stocchi ; Eduardo Tolosa | A double-blind, delayed-start trial of rasagiline in Parkinson's disease. |
| 000B24 (2009) |
Connie Marras [Canada] ; Anthony Lang [Canada] ; Shirley Eberly [États-Unis] ; David Oakes [États-Unis] ; Stanley Fahn [États-Unis] ; Steven Schwid [États-Unis] ; Christopher Hyson [Canada] ; Ira Shoulson [États-Unis] | A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts |
| 000B54 (2008) |
G. Schifitto ; J Friedman ; D. Oakes ; L. Shulman ; C Comella ; K. Marek ; S. Fahn | Fatigue in levodopa-naïve subjects with Parkinson disease |
| 000B67 (2008) |
Michael Schwarzschild ; Steven Schwid ; Kenneth Marek ; Arthur Watts ; Anthony Lang ; David Oakes ; Ira Shoulson ; Alberto Ascherio | 1!Serum urate as a predictor of clinical and radiographic progression in Parkinson’s disease |
| 000D21 (2008) |
C Olanow [États-Unis] ; Robert Hauser [États-Unis] ; Joseph Jankovic [États-Unis] ; William Langston [États-Unis] ; Anthony Lang [Canada] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Fabrizio Stocchi [Italie] ; Eldad Melamed [Israël] ; Eli Eyal [Israël] ; Olivier Rascol [France] | A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics |
